Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Triple Negative Breast Neoplasms 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Advanced Solid Tumors 1

Interventions

pembrolizumab 7Nivolumab 6enfortumab vedotin 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ipilimumab 4sacituzumab govitecan 3Docetaxel 3CTLA-4 Antigen 3cabozantinib 2Taxes 2Paclitaxel 2Gemcitabine 2temsirolimus 1relatlimab 1lenvatinib 1eribulin 1avelumab 1atezolizumab 1Valproic Acid 1Sirolimus 1Single Person 1Radiosurgery 1Platinum 1Immunoglobulin G 1Disulfides 1Cisplatin 1Cetuximab 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × sacituzumab govitecan × 30 days × Clear all
NCT06161532 2026-06-05

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04579224 2026-05-29

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡